AVALO THERAPEUTICS INC (AVTX) Stock News

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company...

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

Mentions: COLL TRVI BHVN

Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside

Avalo Therapeutics' AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates coverage with a $36 price target.

Mentions: ABBV HQY

This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Mentions: ASMB OMF CRNX CWEN

Avalo Reports 2024 Financial Results and Recent Business Updates

Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy...

AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Avalo Therapeutics (NASDAQ:AVTX) just reported results for the second quarter o...

AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q2 2024

AVTX stock results show that Avalo Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

AVTX Stock Earnings: Avalo Therapeutics Misses EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Avalo Therapeutics (NASDAQ:AVTX) just reported results for the fourth quarter o...

Avalo Reports 2024 Financial Results and Recent Business Updates

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

WAYNE, Pa. and ROCKVILLE, Md. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused...

Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Avalo Therapeutics (NASDAQ:AVTX) just reported results for the first quarter of...

AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q1 2024

AVTX stock results show that Avalo Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused...

Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

Proceeds from the full exercise of warrants issued in the first quarter of 2024 private placement bring the total gross proceeds from the transaction to...

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

Avalo Therapeutics to Present at Upcoming Investor Conferences

WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused...

Avalo Therapeutics to Present at Upcoming Investor Conferences

Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates

Dosed first patient in Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa (HS), with topline data expected in 2026Cash position...

Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Global study in approximately 180 adults with hidradenitis suppurativa to assess the efficacy and safety of two dose regimens of AVTX-009 compared to...

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Avalo Announces Participation in September Investor Conferences

Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates

Expects to enroll first patient in Phase 2 LOTUS Trial of AVTX-009 in hidradenitis suppurativa in the second half of 2024Appointed Dr. Mittie Doyle as...

Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates

The 3 Best Personalized Nutrition Stocks to Buy Now

Explore personalized nutrition stocks capitalizing on AI, machine learning and genetic profiling to provide targeted dietary solutions.

Mentions: ME VCYT

Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer

WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has...

Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa

Following FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS) to evaluate the efficacy and...

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa

Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer

WAYNE, Pa. and ROCKVILLE, Md., June 24, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Paul Varki has joined the...

Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer

Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit

WAYNE, Pa. and ROCKVILLE, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief...

Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit

AVTX Stock Earnings: Avalo Therapeutics Misses EPS, Beats Revenue for Q4 2023

AVTX stock results show that Avalo Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.